Repurposing mebendazole against triple-negative breast cancer CNS metastasis

Adrian J. Rodrigues,Sophia B. Chernikova,Yuelong Wang,Thy T. H. Trinh,David E. Solow-Cordero,Ludmila Alexandrova,Kerriann M. Casey,Elizabeth Alli,Abhishek Aggarwal,Tyler Quill,Ashley K. Koegel,Brian J. Feldman,James M. Ford,Melanie Hayden-Gephart
DOI: https://doi.org/10.1007/s11060-024-04654-x
2024-04-03
Journal of Neuro-Oncology
Abstract:Triple-negative breast cancer (TNBC) often metastasizes to the central nervous system (CNS) and has the highest propensity among breast cancer subtypes to develop leptomeningeal disease (LMD). LMD is a spread of cancer into leptomeningeal space that speeds up the disease progression and severely aggravates the prognosis. LMD has limited treatment options. We sought to test whether the common anti-helminthic drug mebendazole (MBZ) may be effective against murine TNBC LMD.
oncology,clinical neurology
What problem does this paper attempt to address?